Reveals dose-dependent HIF stabilization in endothelial cells, suggesting a framework for ischemic disease modeling.
Summary In conditions such as cancer, cardiovascular diseases, and retinal diseases, cells under hypoxia activate oxygen-sensing mechanisms, promoting adaptation and survival. Many hypoxia computational models predate standardized identifiability analyses and lack systematic treatment of the HIF isoform-specific dynamics in endothelial cells. We present a technically validated mechanistic model of the HIF pathway in endothelial cells, capturing graded oxygen sensitivity and the transition from HIF1α-dominated acute to HIF2α-dominated prolonged hypoxic responses. Following identifiability analyses, the model was calibrated and validated against independent datasets, achieving Pearson correlations of 0.7–0.95 and no systematic residual bias (Runs test p ≥ 0.35). Simulations revealed dose-dependent HIF stabilization and VEGFA mRNA induction, a time-dependent shift in transcriptional control from HIF1α to HIF2α, and non-redundant isoform-specific effects of PHD2 and PHD3 inhibition. This validated model provides a robust mechanistic framework for studying endothelial hypoxia signaling, suitable for integration into larger computational models of ischemic disease.
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: